Amoy Diagnostics Co., Ltd. (SHE:300685)

Market Cap	8.97B
Revenue (ttm)	1.13B
Net Income (ttm)	290.10M
Shares Out	386.86M
EPS (ttm)	0.74
PE Ratio	31.40
Forward PE	26.64
Dividend	0.30 (1.29%)
Ex-Dividend Date	Jun 3, 2025

Volume	7,068,484
Average Volume	6,236,486
Open	22.56
Previous Close	23.04
Day's Range	22.56 - 23.43
52-Week Range	19.27 - 27.97
Beta	0.76
RSI	51.95
Earnings Date	Oct 25, 2025

About Amoy Diagnostics

Amoy Diagnostics Co., Ltd. engages in research and development, production, sale, and supporting services of tumor precision medical diagnostic products in China and internationally. The company offers AmoyDx homologous recombination deficiency (HRD) focus panel solutions, evaluates PARP inhibitor-related biomarkers and advances targeted treatment research in ovarian cancer; AmoyDx HRD complete panel, detects genetic aberrations across HRR genes and HRD status; AmoyDx master panel, a CGP assay; AmoyDx BRCA Pro panel, covers various protein codi...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2008
• Employees: 1,144
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300685

Financial Performance

In 2024, Amoy Diagnostics's revenue was 1.11 billion, an increase of 6.27% compared to the previous year's 1.04 billion. Earnings were 254.86 million, a decrease of -2.53%.